

LESLIE C. COOPER, Esq. *Director*

633 Indiana Avenue, NW Suite 1120 Washington, DC 20004

(202) 220-5500

www.PSA.gov

EXECUTIVE COMMITTEE

HON. ANNA BLACKBURNE-RIGSBY Chair Chief Judge District of Columbia Court of Appeals

HON. MERRICK B. GARLAND Chief Judge United States Court of Appeals for the District of Columbia Circuit

HON. BERYL A. HOWELL Chief Judge United States District Court for the District of Columbia

HON. ROBERT E. MORIN Chief Judge Superior Court of the District of Columbia

HON. RICHARD S. TISCHNER Director Court Services and Offender Supervision Agency for the District of Columbia

HON. JESSIE K. LIU United States Attorney for the District of Columbia

AVIS E. BUCHANAN, Esq. Director Public Defender Service for the District of Columbia

PRETRIAL SERVICES AGENCY *for the* DISTRICT *of* COLUMBIA

MEMORANDUM

TO: Interested Parties

Leslie C. CooperAlsuic Cooper FROM:

DATE: April 10, 2019

SUBJECT: March 2019 Drug Testing Statistics

The rate of positive results from drug testing of adult arrestees for March 2019 remained consistent when compared to the previous month, with an overall positive test rate of 26%. Multi-drug positives, opiates and heroin each revealed a 1% increase. Cocaine, amphetamines, PCP, and synthetic cannabinoids each remained consistent.

If you have any questions or need additional information, please contact us at <u>contact@psa.gov</u>. Historical reports dating to 1996 can be accessed at <u>www.psa.gov</u> in the *Reading Room*, which can be accessed under the *Resources* tab.

The breakdown of March 2019 adult test results is as follows:

	February 2019			March 2019				
No. Tests/No. Positive	1195		307 (26%)		1388		357 (26%)	
		s % of ll Tests		s % of Positives		s % of 1Tests		s % of Positives
Multi-Drug Positive	59	(5%)	59	(19%)	83	(6%)	83	(23%)
Cocaine Positive	173	(14%)	173	(56%)	193	(14%)	193	(54%)
Opiates Positive	52	(4%)	52	(17%)	72	(5%)	72	(20%)
Amphetamines Positive	20	(2%)	20	(7%)	33	(2%)	33	(9%)
PCP Positive	97	(8%)	97	(32%)	107	(8%)	107	(30%)
Heroin Positive	5	(0%)	5	(2%)	14	(1%)	14	(4%)
Synthetic Cannabinoid								
Positive	8	(1%)	8	(3%)	7	(1%)	7	(2%)

	March 2019 Tests			
All Negative	1031	74%		
Any Positive	357	26%		
Total	1388	100%		

March 2019 Juvenile Drug Testing Statistics

The positive rate for juvenile drug testing for March 2019 decreased by 6% when compared to the previous month.

	Februa	ary 2019	Marc	ch 2019
Number Tested/ Number Positive	80/53	(66%)	77/46	(60%)
Multi-Drug Positive	2	(3%)	0	(0%)
Cocaine Positive	1	(1%)	0	(0%)
Marijuana Positive	53	(66%)	46	(60%)
PCP Positive	1	(1%)	0	(0%)

The Juvenile Drug Testing Unit tested 77 respondents prior to their appearance in March 2019. Of the 77 lockup cases, 46 (60%) tested positive for marijuana. No community cases were tested for the month of March.

	Co	ommunity]	Lockup	Co	ombined
All Negative	0	(0%)	31	(40%)	31	(40%)
Any Positive	0	(0%)	46	(60%)	46	(60%)
Total	0	(0%)	77	(100%)	77	(100%)

	Of the 0 Community Cases	Of the 77 Lockup Cases	Of the 77 Combined Cases	Of the 46 Positive Cases
Multi-Drug Positive	- (-%)	0 (0%)	0 (0%)	0 (0%)
Cocaine Positive	- (-%)	0 (0%)	0 (0%)	0 (0%)
Marijuana Positive	- (-%)	46 (60%)	46 (60%)	46 (100%)
PCP Positive	- (-%)	0 (0%)	0 (0%)	0 (0%)

The following breakdown of age groups for both community and lockup cases was obtained through the Superior Court's records system, and correlated with the respondent's test result information.


Age	Number of Arrestees Tested	Number Positive for Any Drug	Percent Positive for Any Drug
12	3	1	33%
13	5	1	20%
14	7	2	29%
15	20	14	70%
16	24	16	67%
17	18	12	67%
Totals	77	46	60%

March 2019					
Positives	84	85.71%			
Negatives	14	14.29%			
Total	98	100%			

Synthetic Cannabinoid Testing Results for March 2019*

	Number of Positive Analogues	Percentage of Positive Analogues
5-fluoro PB-22 3-Carboxyindole	54	46.15%
*AB-FUBINACA Metabolites	46	39.32%
PB-22 N-pentanoic acid	6	5.13%
AB-PINACA pentanoic acid	4	3.42%
ADBICA N-pentanoic acid	4	3.42%
UR-144 pentanoic acid	2	1.71%
MAB-CHMINACA M1	1	0.85%
Total	117	100%

***Data is expressed as a percentage of total positive analogues instead of percentage of total samples. Data prior to July 2017 is expressed as a percentage of total samples. Test Performed by LCMSMS *Includes Metabolites 3 and 4 as of June 2017 **Added June 2017.



*These samples were obtained from the pretrial, parole/probation, and juvenile populations. The samples have been preselected by staff or the court for testing due to suspected use by the contributor.

